国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (8): 619-621.doi: 10.3760/cma.j.issn.1673422X.2015.08.016

• 综述 • 上一篇    下一篇

抗血管生成治疗头颈部鳞状细胞癌的研究进展

尚艺泰,李晓江   

  1. 650118昆明医科大学第三附属医院头颈外科 云南省头颈肿瘤研究中心
  • 出版日期:2015-08-08 发布日期:2015-06-29
  • 通讯作者: 李晓江,Email: wingman11@163.com E-mail:wingman11@163.com

Progress on antiangiogenesis treating head and neck squamous cell carcinoma

 SHANG  Yi-Tai, LI  Xiao-Jiang   

  1. Department of Head and Neck Surgery, Third Affiliated Hospital of Kunming Medical University, Research Center of Head and Neck Tumor, Yunnan Province, Kunming 650118, China
  • Online:2015-08-08 Published:2015-06-29
  • Contact: Li Xiaojiang E-mail:wingman11@163.com

摘要: 目前对于复发或转移头颈部鳞状细胞癌(HNSCC)以姑息性化疗及EGFR靶向治疗为主,肿瘤血管的形成是肿瘤生长和远处转移的关键因素,因此,促进血管生成的因子及其受体成为靶向治疗的靶点,目前抗血管生成药物主要通过阻断VEGFVEGF受体(VEGFR)通路,其在治疗HNSCC的临床试验中取得一定效果,为治疗HNSCC提供更多选择。

关键词: 头颈部肿瘤, 血管生成抑制剂, 血管内皮生长因子A

Abstract: Current treatment strategies for recurrent or metastatic head and neck squamous cell carcinoma(HNSCC) include palliative chemotherapy and antiEGFR targeted agents. Angiogenesis is crucial both for the growth of a primary tumor and the development of distant metastasis. Therefore, the angiogenesis factors and their receptors become the targets of therapeutic agents. Current antiangiogenesis drugs achieve the purpose of treatment mainly by blocking VEGFVEGFR pathways. And it gets certain effects in clinical trials for the treatment of HNSCC. Antiangiogenesis therapy will provide more choices for treating HNSCC.

Key words: Head and neck neoplasms, Angiogenesis inhibitors, Vascular endothelial growth factor A